Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Invivyd, Inc.
  6. News
  7. Summary
    IVVD   US00534A1025

INVIVYD, INC.

(IVVD)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-26 pm EST
2.390 USD   -1.24%
01/24Morgan Stanley Trims Invivyd Price Target to $2 From $3, Maintains Underweight Rating
MT
01/09Invivyd : J.P. Morgan 41st Annual Healthcare Conference
PU
01/09Invivyd, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19

11/17/2022 | 07:00am EST

Invivyd, Inc. announced a partnership with Population Health Partners, L.P. (PHP) a global life-science firm dedicated to solving the health and economic challenges presented by prevalent diseases. Through the partnership, Invivyd will leverage PHP's best-in-class clinical development and regulatory expertise to help optimize Invivyd's product development programs. PHP – an investment firm focused on deploying its proven strategic and operating expertise to solve the health and economic challenges presented by the most prevalent and costly diseases of time – will advise and counsel Invivyd on clinical trials and strategies to navigate the regulatory process. PHP will also provide change management guidance to strengthen and augment Invivyd's internal work processes towards achieving maximum speed and efficiency for delivering antibodies for the prevention and treatment of viral infections to high-need populations.


ę S&P Capital IQ 2022
All news about INVIVYD, INC.
01/24Morgan Stanley Trims Invivyd Price Target to $2 From $3, Maintains Underweight Rating
MT
01/09Invivyd : J.P. Morgan 41st Annual Healthcare Conference
PU
01/09Invivyd, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2022Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways ..
GL
2022Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways ..
AQ
2022Invivyd, Inc.(NasdaqGM:IVVD) added to NASDAQ Biotechnology Index
CI
2022Invivyd Names Jeremy Gowler as Chief Operating, Commercial Officer
MT
2022Invivyd, Inc. : Change in Directors or Principal Officers, Other Events, Financial Stateme..
AQ
2022Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete..
GL
2022Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete..
AQ
More news
Analyst Recommendations on INVIVYD, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -238 M - -
Net cash 2022 381 M - -
P/E ratio 2022 -1,11x
Yield 2022 -
Capitalization 264 M 264 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 102
Free-Float 72,5%
Chart INVIVYD, INC.
Duration : Period :
Invivyd, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVIVYD, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Last Close Price 2,42 $
Average target price 2,75 $
Spread / Average Target 13,6%
EPS Revisions
Managers and Directors
David Hering Chief Executive Officer & Director
Frederick W. Driscoll Chief Financial & Accounting Officer
Marc W. Elia Chairman
Laura Walker Chief Scientific Officer
Rebecca L. Dabora Chief Technology & Manufacturing Officer
Sector and Competitors
1st jan.Capi. (M$)
INVIVYD, INC.61.33%264
VERTEX PHARMACEUTICALS8.58%80 930
REGENERON PHARMACEUTICALS, INC.0.83%79 159
WUXI APPTEC CO., LTD.20.37%42 279
BIONTECH SE-4.99%34 686
BEIGENE, LTD.19.81%27 392